<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165292</url>
  </required_header>
  <id_info>
    <org_study_id>2015-003130-27</org_study_id>
    <secondary_id>2015/2294</secondary_id>
    <nct_id>NCT03165292</nct_id>
  </id_info>
  <brief_title>Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy</brief_title>
  <acronym>VERITAS</acronym>
  <official_title>An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SIOPEN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French National Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the efficacy of two intensified consolidation strategies in
      very-high risk neuroblastoma (VHR-NBL) patients in terms of event-free survival from
      randomisation date. This evaluation will follow a hierarchical testing procedure: each
      experimental treatment will be first evaluated as a single-arm phase 2 study, and in case of
      positive conclusion, the relative efficacy of both arms will then be evaluated comparatively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>From the randomisation into the VERITAS trial to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Very High Risk Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A: High administered activity 131I- mIBG and Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The trial will evaluate two randomised arms. Each arm includes
three cycles of Temozolomide-Irinotecan, similar in both arms,
a specific consolidation course detailed hereinafter,
a BuMel sequence, followed by an ASCT, similar in both arms,
external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: High dose Thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The trial will evaluate two randomised arms. Each arm includes
three cycles of Temozolomide-Irinotecan, similar in both arms,
a specific consolidation course detailed hereinafter,
a BuMel sequence, followed by an ASCT, similar in both arms,
external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>131I- mIBG</intervention_name>
    <description>Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy</description>
    <arm_group_label>Arm A: High administered activity 131I- mIBG and Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily</description>
    <arm_group_label>Arm A: High administered activity 131I- mIBG and Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Day 1-3 Thiotepa 300 mg/m²/day</description>
    <arm_group_label>Arm B: High dose Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplant</intervention_name>
    <description>ASCT as soon as radiation level allows it in ARM A</description>
    <arm_group_label>Arm A: High administered activity 131I- mIBG and Topotecan</arm_group_label>
    <arm_group_label>Arm B: High dose Thiotepa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Metastatic neuroblastoma (NBL)

          2. - Patient previously treated within the ongoing High Risk Neuroblastoma SIOPEN study

          3. - mIBG scintigraphy positive at diagnosis and after induction chemotherapy (pre BuMel
             evaluation).

          4. - Metastatic response after induction chemotherapy lower than the ongoing High Risk
             Neuroblastoma SIOPEN trial criteria to be eligible for High Dose Chemotherapy
             (metastatic response worse than partial response (&lt; PR) or SIOPEN score ≥ 3)

          5. - Females of childbearing potential must have a negative serum pregnancy test within 7
             days prior to initiation of treatment. Sexually active patients must agree to use
             acceptable and appropriate contraception while on study drug and for one year after
             stopping the study drug. Acceptable contraception are defined in CTFG Guidelines
             &quot;Recommendations related to contraception and pregnancy testing in clinical trials&quot;.
             Female patients who are lacting must agree to stop breast-feeding.

          6. - Written informed consent from parents/legal representative, patient, and
             age-appropriate assent before any study-specific screening procedures are conducted
             according to local regional or national guidelines.

          7. - Patient affiliated to a social security regimen or beneficiary of the same according
             to local requirements.

        Exclusion Criteria:

          1. - Parenchymal brain metastasis (even one)

          2. - Progressive disease at study entry

          3. - Previous high-dose therapy and PBSCT

          4. - Performance status (Karnofsky, Lansky) &lt;70%

          5. - Patient having received other therapy for cancer treatment than those allowed as per
             the ongoing High Risk Neuroblastoma SIOPEN trial or as defined in the future
             frontlines protocol (for HRNBL1 trial : after induction + 2 TVD)

          6. - Impaired organ function (liver, kidney, heart, lungs)

               -  Shortening fraction &lt;28%, or ejection fraction &lt;55%, or clinical evidence of
                  congestive heart failure or uncontrolled cardiac rythm disturbance

               -  Dyspnea at rest and/or pulse oxymetry &lt;95% in air

               -  ALT, Bilirubin ≤ 2 ULN

               -  Creatinine clearance and/or GFR ≥ 60 ml/min/1.73m2 and serum creatinine &lt; 1.5
                  mg/dl

          7. - Any uncontrolled intercurrent illness or infection that in the investigator's
             opinion would impair study participation

          8. - Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines

          9. - Patient allergic to peanut or soya

         10. - Chronic inflammatory bowel disease and/or bowel obstruction

         11. - Pregnant or breastfeeding women

         12. - Known hypersensitivity to the active substance or to any of the excipients of study
             drugs

         13. - Known hypersensitivity to dacarbazine

         14. - Concomitant use with St John's Wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique VALTEAU COUANET, MD, PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.valteau-couanet@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Cécile LE DELEY, MD</last_name>
    <phone>0320295893</phone>
    <phone_ext>+33</phone_ext>
    <email>m-ledeley@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan RUBINO</last_name>
      <phone>0142113891</phone>
      <phone_ext>+33</phone_ext>
      <email>jonathan.rubino@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille JANNIN</last_name>
      <phone>0142114884</phone>
      <phone_ext>+33</phone_ext>
      <email>camille.jannin@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique VALTEAU COUANET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

